Chapter 20 — Further Reading

Endorphins, Enkephalins, and the Opioid Peptides

This list is tiered by how much you should trust the citation as printed here. That is not a courtesy; it is the same discipline the chapter applies to evidence. A reading list that presents a half-remembered attribution with the same confidence as a canonical reference is doing the reader a disservice, and the peptide literature is full of exactly that.

Tier 1 — Verified canonical

These are foundational works and reference sources whose existence and general content are not in doubt. Names, journals, and approximate dates are reliable. Verify page numbers and exact titles yourself before citing in anything formal.

Hughes, J., Smith, T. W., Kosterlitz, H. W., et al. (1975). Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. The discovery of the enkephalins. Read it for the moment the field inverted — the receptors had been characterized, and here are the molecules they were built for.

Levine, J. D., Gordon, N. C., & Fields, H. L. (1978). The mechanism of placebo analgesia. The Lancet. The naloxone-reversal experiment, and the anchor of Case Study 20.1. It is short. Read the actual paper rather than a description of it; the design is more constrained and more careful than its reputation suggests.

Amanzio, M., & Benedetti, F. (1999). Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. The Journal of Neuroscience. The dissociation that turned a finding into a theory. This is the paper that establishes "the placebo effect" is not one thing.

Fields, H. L. (2004). State-dependent opioid control of pain. Nature Reviews Neuroscience. The best single review of descending modulation, including the facilitatory arm that a purely inhibitory model cannot accommodate. If you read one review from this list, read this one.

Goodman & Gilman's The Pharmacological Basis of Therapeutics, current edition, chapter on opioid analgesia. The standard reference for receptor pharmacology, clinical effects, tolerance, and the distinction between dependence and use disorder. Dry and correct.

FDA prescribing information for ziconotide (Prialt). Freely available. Worth reading precisely because it is not a review article: the route of administration, the boxed warning, and the defined patient population tell you more about the difficulty of this target than a narrative summary would. Do the same for difelikefalin (Korsuva) and note the indication carefully — pruritus, not pain.

National Institute on Drug Abuse and Substance Abuse and Mental Health Services Administration materials on opioid use disorder. For the clinical and epidemiological material in §20.6. Use primary public-health sources here rather than secondary commentary; the topic attracts a great deal of confident writing that is not grounded in the treatment literature.

Tier 2 — Attributed, specifics unverified

These works are real and the attributions are as accurate as I can make them, but you should confirm author lists, years, and journals before relying on any specific detail. Where the chapter describes a result from this tier, it describes it in general terms for exactly this reason.

Pert, C. B., & Snyder, S. H. (1973). Opiate receptor: demonstration in nervous tissue. Science. One of several near-simultaneous demonstrations — work by Simon and by Terenius appeared in the same period, and priority is genuinely shared. Cite the cluster, not a single paper, unless you have checked.

Goldstein, A., and colleagues (late 1970s). Isolation and characterization of dynorphin. The naming reflects the peptide's unusual potency in bioassay. Confirm the specific paper before citing.

Reynolds, D. V. (1969). Surgery in the rat during electrical analgesia induced by focal brain stimulation. Science. The stimulation-produced analgesia result described in §20.4. The subsequent demonstration that naloxone attenuates stimulation-produced analgesia comes from several groups across the 1970s; treat that as a body of work rather than a single citation.

Boecker, H., et al. (2008). The runner's high: opioidergic mechanisms in the human brain. Cerebral Cortex. PET with an opioid receptor ligand in trained athletes before and after endurance running. Small sample, correlational design, real result. Read the methods section specifically, and notice how much more cautious the paper is than its citations.

Fuss, J., et al. (2015). A runner's high depends on cannabinoid receptors in mice. PNAS. The rodent dissociation. Note the operational definitions of "runner's high" in a mouse — anxiety-like behavior and nociceptive threshold — and consider what they can and cannot stand in for.

Siebers, M., et al. (2021). Work reporting that exercise-induced euphoria in humans persisted under opioid receptor blockade. Psychoneuroendocrinology. Verify authors and year; the finding is the relevant part and it is a null result in a single paradigm.

Zubieta, J.-K., et al. (2005). PET imaging of mu-opioid receptor activation during placebo analgesia. The Journal of Neuroscience. The independent-method corroboration in Case Study 20.1.

de la Fuente-Fernández, R., et al. (2001). Expectation and dopamine release in placebo response in Parkinson's disease. Science. The cleanest demonstration that a placebo effect can be non-opioid-mediated.

Wisner, A., et al. (2006). Characterization of opiorphin, a human peptide inhibitor of enkephalin-degrading ectopeptidases. PNAS. Background for the dual-enkephalinase-inhibitor material in §20.9.

Tier 3 — Illustrative and constructed

Nothing in this tier is a citation. These are teaching constructions, and they are labeled so you never mistake one for a source.

"Two pools, one name" (Case Study 20.2). The blood-versus-brain β-endorphin diagram is a teaching schematic drawn for this chapter, not a reproduction of a published figure. The underlying facts — pituitary co-release with ACTH, blood-brain barrier impermeability to a 31-residue peptide — are standard; the picture is mine.

The three-joint test (magnitude / duration / existence proof). A framework built in Chapter 13 for this book. It is a reasoning tool, not a published methodology, and you will not find it under that name in the literature.

The message-address framing of the opioid peptides. This is a real concept in peptide pharmacology with a real history, but the specific presentation in §20.2 — the aligned sequence block showing nociceptin's tyrosine-to-phenylalanine substitution as a subtraction experiment — is a teaching arrangement built here.

The 📊 Evidence Rating format and all ratings in this chapter. These are this book's editorial judgments as of 2026, made using the rules in Chapter 5. They are not consensus statements, guideline recommendations, or regulatory determinations. They are date-stamped and falsifiable on purpose. Where one differs from a rating you would assign, the difference is the useful part.

All marketing copy quoted in the ⚠️ Hype Check callout. Composite constructions. They are written to be representative of a genre rather than to reproduce any specific product's claims, and no real company's language is quoted.

If you only do one thing

Read the 1978 Lancet paper by Levine, Gordon, and Fields, and then read the 1999 Amanzio and Benedetti paper immediately after.

Together they take about an hour. The first shows you an experiment converting an unanswerable question into an answerable one by refusing to argue about reports and asking a receptor instead. The second shows you what happens next when a field takes its own result seriously — the finding gets harder, not simpler, and the complication is the discovery.

That pairing is the whole method of this book in two papers. Everything else on this list is elaboration.